EVAR术后内漏风险的血浆基质金属蛋白酶纵向评估
这项前瞻性单中心观察性队列研究纳入100例择期肾下腹主动脉瘤EVAR患者,在基线、术后7天、6个月和12个月检测9种MMP亚型,发现内漏组术前MMP-1和MMP-2显著升高,术后7天MMP-1和MMP-9区分能力最强,12个月MMP-9和MMP-10仍独立相关,联合模型AUC可达0.880。
要点
- 术前MMP-1和MMP-2升高与EVAR术后内漏风险相关。
- 术后7天MMP-1和MMP-9联合模型区分内漏的AUC为0.827。
- 12个月MMP-9和MMP-10联合模型AUC为0.861,可辅助个性化随访。
核心结论
- 动态MMP谱(术前MMP-1和MMP-2、术后早期MMP-1和MMP-9、晚期MMP-9和MMP-10)能准确识别EVAR术后内漏高风险患者。
研究设计与样本
- 前瞻性单中心观察性队列研究,纳入2022年7月至2024年7月间100例连续接受择期肾下腹主动脉瘤EVAR的患者。
主要发现
- 随访期间24例患者发生内漏。
- 术前内漏组MMP-1和MMP-2水平显著更高(p < .010)。
- 术后7天MMP-1和MMP-9区分能力最强(p < .001)。
- 12个月MMP-9和MMP-10仍独立与内漏相关(p < .010)。
- 联合模型AUC分别为0.880(MMP-1+MMP-2,基线)、0.827(MMP-1+MMP-9,7天)和0.861(MMP-9+MMP-10,12个月)。
关键数值与推荐
- 基线MMP-1约15 μg/mL、术后7天MMP-9约42 μg/mL、12个月MMP-10约2 μg/mL为临床相关截断值。
临床怎么用
- 将MMP测量纳入随访方案可能补充影像学检查,实现EVAR术后个性化监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether plasma concentrations of a comprehensive panel of matrix metalloproteinases (MMPs), measured at baseline and during follow up, are associated with the development of endoleak after endovascular aortic repair (EVAR), and to establish clinically relevant thresholds for post-operative risk stratification. METHODS: This was a prospective, single centre, observational cohort study including 100 consecutive patients undergoing elective infrarenal EVAR between July 2022 and July 2024. Plasma levels of nine MMP isoforms (MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-12, and MMP-13) were quantified using an enzyme linked immunosorbent assay at baseline, seven days, six and 12 months. Endoleak was diagnosed on scheduled computed tomography angiography at one, six, and 12 months, independently adjudicated by two radiologists blinded to biochemical data. Associations between MMP concentrations and endoleak were analysed with independent t tests, effect sizes, and multivariable logistic regression. Predictive accuracy was assessed with receiver operating characteristic curves, and optimal cutoff values were derived using the Youden index. RESULTS: During follow up, 24 patients developed endoleak. Pre-operatively, MMP-1 and MMP-2 levels were statistically significantly higher in the endoleak group (p < .010). At seven days, MMP-1 and MMP-9 were the strongest discriminators (p < .001), while at 12 months, MMP-9 and MMP-10 remained independently associated with endoleak (p < .010). Combined models consistently outperformed individual biomarkers, with areas under the receiver operating characteristic curve of 0.880 (MMP-1 + MMP-2, baseline), 0.827 (MMP-1 + MMP-9, seven days), and 0.861 (MMP-9 + MMP-10, 12 months). Clinically relevant cutoff values were identified: ∼15 μg/mL for MMP-1 at baseline, ∼42 μg/mL for MMP-9 at seven days, and ∼2 μg/mL for MMP-10 at 12 months. CONCLUSION: A dynamic biomarker profile, MMP-1 and MMP-2 pre-operatively, MMP-1 and MMP-9 early post-operatively, and MMP-9 and MMP-10 at late follow up, accurately identified patients at risk of endoleak. Incorporating MMP measurements into follow up protocols may complement imaging and enable personalised surveillance after EVAR.
引用
- Del Río-Solá ML, Álvarez-Garcia E, Jimenez-Caja M, et al. A Comprehensive Longitudinal Evaluation of Pre-operative and Post-operative Plasma Matrix Metalloproteinases for Identifying Patients at Increased Risk of Endoleak after Endovascular Aneurysm Repair. Eur J Vasc Endovasc Surg. 2026. PMID: 41520770. doi:10.1016/j.ejvs.2026.01.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。